BidaskClub downgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a buy rating to a hold rating in a report published on Saturday.
Several other research analysts have also weighed in on AIMT. Wedbush reiterated an ourperform rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, August 14th. Zacks Investment Research lowered shares of Aimmune Therapeutics from a buy rating to a hold rating in a research note on Wednesday, December 6th. ValuEngine lowered shares of Aimmune Therapeutics from a hold rating to a sell rating in a research note on Friday, December 1st. Piper Jaffray Companies upped their price objective on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the company an overweight rating in a research note on Tuesday, December 5th. Finally, Roth Capital assumed coverage on shares of Aimmune Therapeutics in a research note on Monday, November 20th. They issued a buy rating and a $60.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. Aimmune Therapeutics presently has a consensus rating of Buy and an average target price of $53.80.
Shares of Aimmune Therapeutics (AIMT) opened at $33.60 on Friday. Aimmune Therapeutics has a 1-year low of $15.97 and a 1-year high of $38.86.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.09. equities analysts expect that Aimmune Therapeutics will post -2.54 earnings per share for the current year.
In other Aimmune Therapeutics news, CEO Stephen George Dilly sold 80,110 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $26.23, for a total value of $2,101,285.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Susan E. Barrowcliffe sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $25.00, for a total transaction of $500,000.00. Following the completion of the transaction, the insider now owns 20,000 shares in the company, valued at approximately $500,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 274,986 shares of company stock worth $7,533,100. Company insiders own 17.59% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its stake in shares of Aimmune Therapeutics by 5.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock worth $1,892,000 after purchasing an additional 4,788 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Aimmune Therapeutics during the 2nd quarter worth $442,000. Goldman Sachs Group Inc. increased its stake in shares of Aimmune Therapeutics by 139.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock worth $4,675,000 after purchasing an additional 132,603 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Aimmune Therapeutics by 16.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock worth $2,700,000 after purchasing an additional 19,016 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Aimmune Therapeutics during the 2nd quarter worth $360,000. Institutional investors own 73.34% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Aimmune Therapeutics (AIMT) Stock Rating Lowered by BidaskClub” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/13/aimmune-therapeutics-aimt-stock-rating-lowered-by-bidaskclub.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.